Ulf Grawunder, PhD (founder and CEO)
Ulf Grawunder is an experienced Swiss Life-Science entrepreneur with over 10 years experience in the therapeutic antibody development industry. With NBE-Therapeutics, he has recently founded his second Swiss Biotech company and is leading NBE-Therapeutics as its CEO since June 2012. Ulf Grawunder has invented two new patent-pending technologies at NBE-Therapeutics that allow the company to develop most highly innovative antibody-based drugs, including next-generation antibody drug conjugates (ADCs) for the therapy of cancer. Before that, Ulf Grawunder co-founded the Swiss Biotech company 4-Antibody, recently sold to U.S.-based Agenus (AGEN), where since 2004 he served as founding CEO and after 2006 assumed the role of CSO. During his tenure at 4-Antibody, Ulf Grawunder raised about CHF 50 million capital for the company, secured two pharma/biotech collaborations with Boehringer Ingelheim, Germany, and Human Genome Sciences, U.S.A. and grew the company to 50 employees. Ulf Grawunder is serving on various Boards of non-profit and for-profit life-science organizations and is vice-president and Board member of the Swiss Biotech Association. Ulf Grawunder holds a PhD in Cell Biology from the University of Basel, for work on early B cell development performed at the Basel Institute for Immunology. In addition, Ulf Grawunder holds a Diploma in Technology Entrepreneurship from the Entrepreneur and Business School in St. Gallen, Switzerland (HSG=Hochschule St. Gallen).
Roger R. Beerli, PhD (Chief Scientific Officer)
Roger Beerli serves as Chief Scientific Officer (CSO) at NBE Therapeutics since April 2013. Roger Beerli has over 10 years of experience in discovery, engineering and preclinical development of therapeutic antibodies. Previously he has led R&D activities related to therapeutic antibody development at Cytos, Switzerland, and later at Intercell, Austria. Roger is a renowned expert in mammalian cell based antibody expression and display for the discovery of fully human therapeutic antibodies. He was the main architect and inventor of Cytos' eMAB® mammalian cell antibody development platform, which, under Roger's leadership, was successfully used for the development of fully human therapeutic antibody candidates against numerous targets, including Nicotine and Influenza A, both at Cytos, and also later at Intercell, after the platform had been acquired by Intercell. Roger Beerli studied molecular biology at the University of Zurich, Switzerland, and obtained his PhD for work at the Novartis-associated Friedrich Miescher Institute in Basel, Switzerland, for research on ErbB receptor tyrosine kinases. Afterwards he performed postdoctoral research at The Scripps Research Institute in La Jolla, California, USA, in the lab of Prof. Dr. Carlos F. Barbas III. Here he specialized in phage display for protein and antibody engineering and was among the first to demonstrate artificial regulation of endogenous genes using engineered transcription factors. Roger Beerli has published widely in the areas of protein discovery, protein engineering and antibody development, and he is co-inventor on numerous patents and patent applications.
- London, 2019-03-05 - NBE-Therapeutics will present at the 9th World ADC Congress Europe in London
- San Diego, USA, 2019-03-04 - NBE-Therapeutics invited to present at Terrapinn's Americas Antibody Congress
- Basel, 2019-01-29 - Unites States Patent and Trademark Office grants US patent on NBE's linker-toxin technology